Arcus Biosciences reported $25 million in revenues and a net loss of $80 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities were $1.0 billion as of March 31, 2023, expected to fund operations into 2026. Clinical development activities are expanding, with multiple Phase 3 and Phase 2 trials ongoing.
Four Phase 3 and two Phase 2 trials are enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers.
The third dose-escalation cohort (100mg) of ARC-20 for AB521 is enrolling, with the dose-expansion stage of ARC-20 and a Phase 2 combination study expected to begin in the third quarter.
Three new drug candidates are expected to advance into the clinic in 2023 and early 2024.
Arcus Biosciences has $1.0 billion in cash, cash equivalents and marketable securities, providing funding into 2026 to advance its pipeline.
Arcus Biosciences is focused on advancing its pipeline and initiating new clinical trials. Data from several ongoing studies are expected in the second half of 2023 and early 2024.
Analyze how earnings announcements historically affect stock price performance